

## Product datasheet for RC208522L1V

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## TAB1 (NM\_006116) Human Tagged ORF Clone Lentiviral Particle

**Product data:** 

**Product Type:** Lentiviral Particles

**Product Name:** TAB1 (NM\_006116) Human Tagged ORF Clone Lentiviral Particle

Symbol:

3'-Tab1; MAP3K7IP1 Synonyms:

**Mammalian Cell** 

Selection:

None

Vector: pLenti-C-Myc-DDK (PS100064)

Myc-DDK Tag: NM 006116 ACCN: **ORF Size:** 1512 bp

**ORF Nucleotide** 

Sequence:

The ORF insert of this clone is exactly the same as(RC208522).

OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through

naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing

variants is recommended prior to use. More info

**OTI Annotation:** This clone was engineered to express the complete ORF with an expression tag. Expression

varies depending on the nature of the gene.

RefSeq: NM 006116.2

RefSeq Size: 3240 bp RefSeq ORF: 1515 bp Locus ID: 10454 **UniProt ID:** Q15750 Cytogenetics: 22q13.1

**Domains:** PP2C

**Protein Families:** Druggable Genome





## TAB1 (NM\_006116) Human Tagged ORF Clone Lentiviral Particle - RC208522L1V

Protein Pathways: MAPK signaling pathway, NOD-like receptor signaling pathway, Toll-like receptor signaling

pathway

**MW:** 54.6 kDa

**Gene Summary:** The protein encoded by this gene was identified as a regulator of the MAP kinase kinase

kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. This protein interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of this protein is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. This protein can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli. Alternatively spliced transcript variants

encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]